Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet Infect Dis, issue.20, pp.30196-30197, 2020. ,
Virological assessment of hospitalized patients with COVID-2019, Nature, 2020. ,
Epidemiology and clinical features of COVID-19: A review of current literature, J Clin Virol, vol.127, p.104357, 2020. ,
Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies, PLoS Negl Trop Dis, vol.11, issue.1, p.5230, 2017. ,
, SARS-CoV-2 diagnostics: performance data. The Foundation for Innovative New Diagnostics (FIND)
Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19), Clin Inf Dis, 2020. ,
SARS-CoV-2 specific antibody responses in COVID-19 patients, medRxiv, 2020. ,
A serological assay to detect SARS-CoV-2 seroconversion in humans, medRxiv, 2020. ,
A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease, medRxiv, 2020. ,
Dynamics of the antibody response to Plasmodium falciparum infection in African children, J Infect Dis, vol.210, pp.1115-1137, 2014. ,
Linking the seroresponse to infection to within-host heterogeneity in antibody production, Epidemics, vol.16, pp.33-39, 2016. ,
Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis A virus, PLoS Comput Biol, vol.8, p.1002418, 2012. ,
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial, Lancet Infect Dis, vol.15, pp.1450-58, 2015. ,
A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine, BMC Med, vol.12, p.117, 2014. ,
Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays. medRxiv, 2020. ,
Beyond the Spike: identification of viral targets of the antibody response to SARS-CoV-2 in COVID-19 patients, medRxiv, 2020. ,
Development and validation of serological markers for detecting recent exposure to Plasmodium vivax infection, Nature Med, 2020. ,
Estimating cholera incidence with cross-sectional serology, Sci Transl Med, vol.11, issue.480, 2019. ,
Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities, Proc Natl Acad Sci, vol.112, issue.32, pp.4438-4485, 2015. ,
Serological signatures of declining exposure following intensification of integrated malaria control in two rural Senegalese communities, PLoS One, vol.12, issue.6, p.179146, 2017. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01635035
Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients, medRxiv, 2020. ,
Clinical and virological data of the first cases of COVID-19 in Europe: a case series, Lancet Inf Dis, issue.20, pp.30200-30200, 2020. ,
URL : https://hal.archives-ouvertes.fr/inserm-02549694
Asymptomatic Plasmodium vivax infections induce robust IgG responses to multiple blood-stage proteins in a low-transmission region of western Thailand, Malar J, vol.16, issue.1, p.178, 2017. ,
Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis, Sci Rep, vol.8, issue.1, p.15701, 2018. ,
The time course of the immune response to experimental coronavirus infection of man, Epidemiol Infect, vol.105, issue.2, pp.435-481, 1990. ,
Duration of antibody responses after severe acute respiratory syndrome, Emerg Infect Dis, vol.13, issue.10, pp.1562-1566, 2007. ,
MERS-CoV antibody responses 1 year after symptom onset, South Korea, Emerg Infect Dis, vol.23, issue.7, pp.1079-1084, 2015. ,
Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome, J Infect Dis, vol.193, pp.792-797, 2006. ,
Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance, Respirology, vol.11, issue.1, pp.49-53, 2006. ,
Disappearance of antibodies to SARS-associated coronavirus after recovery, N Engl J Med, vol.357, issue.11, pp.1162-1165, 2007. ,
Antibody responses to merozoite antigens after natural Plasmodium falciparum infection: kinetics and longevity in absence of re-exposure, BMC Med, vol.17, issue.1, p.22, 2019. ,
Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice, MedRxiv, 2020. ,
Evaluation of nine commercial SARS-CoV-2 immunoassays, medRxiv, 2020. ,
SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors, medRxiv, 2020. ,
Surrogate endpoints in clinical-trials-definition and operational criteria, Stat Med, vol.8, pp.431-471, 1989. ,
A framework for assessing immunological correlates of protection in vaccine trials, J Infect Dis, vol.196, pp.1304-1316, 2007. ,
Antibody kinetics following vaccination with MenAfriVac and implications for the duration of protection: an analysis of serological data, Lancet Inf Dis, vol.19, issue.3, pp.327-336, 2019. ,